Manufacturers: CureGene Pharmaceutical
CG-0416 is a novel oral liver-targeting THR-β agonist prodrug developed by CureGene for chronic metabolic diseases including MASH and obesity. In August 2026 CureGene announced first-subject dosing in a Phase I first-in-human trial in Australia. Preclinical data show weight-loss efficacy comparable to GLP-1 receptor agonists (e.g., semaglutide) with muscle preservation, reduced liver fat, up to 92% oral bioavailability, and a non-CYP metabolism pathway.
CG-0416 is a novel oral liver-targeting THR-β agonist prodrug developed by CureGene for chronic metabolic diseases including MASH and obesity. In August 2026 CureGene announced first-subject dosing in a Phase I first-in-human trial in Australia. Preclinical data show weight-loss efficacy comparable to GLP-1 receptor agonists (e.g., semaglutide) with muscle preservation, reduced liver fat, up to 92% oral bioavailability, and a non-CYP metabolism pathway.
In development (Phase I, not yet approved) as an oral therapy for chronic metabolic diseases, including obesity and metabolic dysfunction-associated steatohepatitis (MASH).
